Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera

View ORCID ProfileKei Miyakawa, Sundararaj Stanleyraj Jeremiah, Hideaki Kato, Yutaro Yamaoka, Hirofumi Go, Takeharu Yamanaka, Akihide Ryo
doi: https://doi.org/10.1101/2021.05.06.21256788
Kei Miyakawa
1Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kei Miyakawa
Sundararaj Stanleyraj Jeremiah
1Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hideaki Kato
2Infection Prevention and Control Department, Yokohama City University Hospital, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yutaro Yamaoka
1Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Japan
3Life Science Laboratory, Technology and Development Division, Kanto Chemical Co, Inc., Isehara, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hirofumi Go
4Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takeharu Yamanaka
4Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, Japan
5Department of Health Data Science, Yokohama City University Graduate School of Data Science, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akihide Ryo
1Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: aryo@yokohama-cu.ac.jp
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The uncontrolled spread of the COVID-19 pandemic has led to the emergence of different SARS-CoV-2 variants across the globe. The ongoing global vaccination strategy to curtail the COVID-19 juggernaut, is threatened by the rapidly spreading Variants of Concern (VOC) and other regional mutants, which are less responsive to neutralization by infection or vaccine derived antibodies. We have previously developed the hiVNT system which detects SARS-CoV-2 neutralizing antibodies in sera in less than three hours. In this study, we modify the hiVNT for rapid qualitative screening of neutralizing antibodies (nAb) to multiple variants of concern (VOC) of SARS-CoV-2, and assess the neutralizing efficacy of the BNT162b2 mRNA vaccine on seven epidemiologically relevant SARS-CoV-2 variants. Here we show that the BNT162b2 mRNA vaccine can activate humoral immunity against the major SARS-CoV-2 mutants that are currently in circulation. Albeit a small sample size, we observed that one dose of vaccine was sufficient to elicit a protective humoral response in previously infected people. Using a panel of seven SARS-CoV-2 variants and a single prototype virus, our modified hiVNT would be useful for large-scale community wide testing to detect protective immunity that may confer vaccine/immune passport in the ongoing COVID-19 pandemic.

Competing Interest Statement

YY is a current employee of Kanto Chemical Co. Inc. The authors have no conflicts of interest directly relevant to the content of this article.

Clinical Trial

N/A

Funding Statement

This study was supported by Rapid research and development Projects on COVID-19 of AMED (JP19fk0108110) to AR.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by Yokohama City University Certified Institutional Review Board (Reference No. B160800009, B200600115, B210300001), and the protocols used in the study were approved by the ethics committee.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The datasets presented in this article are not readily available because it is difficult to ensure the de-identification of data. However, they can be available from the corresponding author on reasonable request. Requests to access the datasets should be directed to AR.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted May 10, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera
Kei Miyakawa, Sundararaj Stanleyraj Jeremiah, Hideaki Kato, Yutaro Yamaoka, Hirofumi Go, Takeharu Yamanaka, Akihide Ryo
medRxiv 2021.05.06.21256788; doi: https://doi.org/10.1101/2021.05.06.21256788
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera
Kei Miyakawa, Sundararaj Stanleyraj Jeremiah, Hideaki Kato, Yutaro Yamaoka, Hirofumi Go, Takeharu Yamanaka, Akihide Ryo
medRxiv 2021.05.06.21256788; doi: https://doi.org/10.1101/2021.05.06.21256788

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (580)
  • Anesthesia (141)
  • Cardiovascular Medicine (1962)
  • Dentistry and Oral Medicine (253)
  • Dermatology (187)
  • Emergency Medicine (335)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (703)
  • Epidemiology (11123)
  • Forensic Medicine (8)
  • Gastroenterology (629)
  • Genetic and Genomic Medicine (3196)
  • Geriatric Medicine (310)
  • Health Economics (567)
  • Health Informatics (2049)
  • Health Policy (864)
  • Health Systems and Quality Improvement (789)
  • Hematology (310)
  • HIV/AIDS (685)
  • Infectious Diseases (except HIV/AIDS) (12742)
  • Intensive Care and Critical Care Medicine (708)
  • Medical Education (318)
  • Medical Ethics (92)
  • Nephrology (337)
  • Neurology (3004)
  • Nursing (165)
  • Nutrition (465)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1561)
  • Ophthalmology (478)
  • Orthopedics (186)
  • Otolaryngology (266)
  • Pain Medicine (202)
  • Palliative Medicine (57)
  • Pathology (403)
  • Pediatrics (914)
  • Pharmacology and Therapeutics (386)
  • Primary Care Research (355)
  • Psychiatry and Clinical Psychology (2799)
  • Public and Global Health (5613)
  • Radiology and Imaging (1101)
  • Rehabilitation Medicine and Physical Therapy (637)
  • Respiratory Medicine (764)
  • Rheumatology (341)
  • Sexual and Reproductive Health (315)
  • Sports Medicine (289)
  • Surgery (348)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (133)